Location, location, location: New insights into O-GalNAc protein glycosylation

Trends in Cell Biology

Volumn 21, Issue 3, 2011, Pages 149-158

  Gill, David J ^a   Clausen, Henrik ^b   Bard, Frederic ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FUCOSE; GALACTOSE; GLUCOSE; GLYCAN; MANNOSE; N ACETYLGALACTOSAMINE; N ACETYLGLUCOSAMINE; PROTEIN; SIALIC ACID; SIALYLTRANSFERASE; URIDINE DIPHOSPHATE; XYLOSE;

BIOSYNTHESIS; CAENORHABDITIS ELEGANS; CANCER CELL; CANCER GROWTH; CELL TRANSFORMATION; DROSOPHILA MELANOGASTER; ENDOPLASMIC RETICULUM; METASTASIS; OVARY CYCLE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; N-ACETYLGALACTOSAMINYLTRANSFERASES; POLYSACCHARIDES; PROTEIN TRANSPORT; SUBSTRATE SPECIFICITY;

EUMETAZOA;

EID: 79952106660     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcb.2010.11.004     Document Type: Review

References (102)

1. Apweiler R., et al. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim. Biophys. Acta 1999, 1473:4-8.
2. Lowe J.B., Marth J.D. A genetic approach to mammalian glycan function. Annu. Rev. Biochem. 2003, 72:643-691.
3. Hart G.W. Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins. Annu. Rev. Biochem. 1997, 66:315-335.
4. Wopereis S., et al. Mechanisms in protein O-glycan biosynthesis and clinical and molecular aspects of protein O-glycan biosynthesis defects: a review. Clin. Chem. 2006, 52:574-600.
5. Luther K.B., Haltiwanger R.S. Role of unusual O-glycans in intercellular signaling. Int. J. Biochem. Cell Biol. 2009, 41:1011-1024.
6. Hashimoto K., et al. Comprehensive analysis of glycosyltransferases in eukaryotic genomes for structural and functional characterization of glycans. Carbohydr. Res. 2009, 344:881-887.
7. Hanisch F.G. O-Glycosylation of the mucin type. Biol. Chem. 2001, 382:143-149.
8. Hang H.C., Bertozzi C.R. The chemistry and biology of mucin-type O-linked glycosylation. Bioorg. Med. Chem. 2005, 13:5021-5034.
9. Garner B., et al. Structural elucidation of the N- and O-glycans of human apolipoprotein(a): role of o-glycans in conferring protease resistance. J. Biol. Chem. 2001, 276:22200-22208.
10. Lang T., et al. Gel-forming mucins appeared early in metazoan evolution. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:16209-16214.
11. Ellies L.G., et al. Core 2 oligosaccharide biosynthesis distinguishes between selectin ligands essential for leukocyte homing and inflammation. Immunity 1998, 9:881-890.
12. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep. 2006, 7:599-604.
13. Tarp M.A., Clausen H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim. Biophys. Acta 2008, 1780:546-563.
14. Clausen H., Bennett E.P. A family of UDP-GalNAc: polypeptide N-acetylgalactosaminyl-transferases control the initiation of mucin-type O-linked glycosylation. Glycobiology 1996, 6:635-646.
15. Ten Hagen K.G., et al. All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology 2003, 13:1R-16R.
16. Tian E., Ten Hagen K.G. Recent insights into the biological roles of mucin-type O-glycosylation. Glycoconj. J. 2009, 26:325-334.
17. Tabak L.A. The role of mucin-type O-glycans in eukaryotic development. Semin. Cell Dev. Biol. 2010, 21:616-621.
18. Brockhausen I., et al. Mucin synthesis. UDP-GlcNAc:GalNAc-R beta 3-N-acetylglucosaminyltransferase and UDP-GlcNAc:GlcNAc beta 1-3GalNAc-R (GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase from pig and rat colon mucosa. Biochemistry 1985, 24:1866-1874.
19. Royle L., et al. Glycan structures of ocular surface mucins in man, rabbit and dog display species differences. Glycoconj. J. 2008, 25:763-773.
20. Argueso P., et al. Association of cell surface mucins with galectin-3 contributes to the ocular surface epithelial barrier. J. Biol. Chem. 2009, 284:23037-23045.
21. Tsuboi S., Fukuda M. Roles of O-linked oligosaccharides in immune responses. Bioessays 2001, 23:46-53.
22. Ungar D. Golgi linked protein glycosylation and associated diseases. Semin. Cell Dev. Biol. 2009, 20:762-769.
23. Springer G.F. T and Tn, general carcinoma autoantigens. Science 1984, 224:1198-1206.
24. Muller S., et al. High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells. J. Biol. Chem. 1999, 274:18165-18172.
25. Kim Y.S., et al. Mucin glycoproteins in neoplasia. Glycoconj. J. 1996, 13:693-707.
26. Hollingsworth M.A., Swanson B.J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 2004, 4:45-60.
27. Ju T., et al. Cloning and expression of human core 1 beta1,3-galactosyltransferase. J. Biol. Chem. 2002, 277:178-186.
28. Vavasseur F., et al. Synthesis of O-glycan core 3: characterization of UDP-GlcNAc: GalNAc-R beta 3-N-acetyl-glucosaminyltransferase activity from colonic mucosal tissues and lack of the activity in human cancer cell lines. Glycobiology 1995, 5:351-357.
29. Iwai T., et al. Molecular cloning and characterization of a novel UDP-GlcNAc:GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase (beta 3Gn-T6), an enzyme synthesizing the core 3 structure of O-glycans. J. Biol. Chem. 2002, 277:12802-12809.
30. Iwai T., et al. Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:4572-4577.
31. Byrd J.C., Bresalier R.S. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004, 23:77-99.
32. Bierhuizen M.F., Fukuda M. Expression cloning of a cDNA encoding UDP-GlcNAc:Gal beta 1-3-GalNAc-R (GlcNAc to GalNAc) beta 1-6GlcNAc transferase by gene transfer into CHO cells expressing polyoma large tumor antigen. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:9326-9330.
33. Schwientek T., et al. Control of O-glycan branch formation. Molecular cloning and characterization of a novel thymus-associated core 2 beta1, 6-n-acetylglucosaminyltransferase. J. Biol. Chem. 2000, 275:11106-11113.
34. Schwientek T., et al. Control of O-glycan branch formation. Molecular cloning of human cDNA encoding a novel beta1,6-N-acetylglucosaminyltransferase forming core 2 and core 4. J. Biol. Chem. 1999, 274:4504-4512.
35. Yeh J.C., et al. Molecular cloning and expression of a novel beta-1, 6-N-acetylglucosaminyltransferase that forms core 2, core 4, and I branches. J. Biol. Chem. 1999, 274:3215-3221.
36. Brockhausen I., et al. Biosynthesis of O-glycans in leukocytes from normal donors and from patients with leukemia: increase in O-glycan core 2 UDP-GlcNAc:Gal beta 3 GalNAc alpha-R (GlcNAc to GalNAc) beta(1-6)-N-acetylglucosaminyltransferase in leukemic cells. Cancer Res. 1991, 51:1257-1263.
37. Piller F., et al. Human T-lymphocyte activation is associated with changes in O-glycan biosynthesis. J. Biol. Chem. 1988, 263:15146-15150.
38. Li F., et al. Post-translational modifications of recombinant P-selectin glycoprotein ligand-1 required for binding to P- and E-selectin. J. Biol. Chem. 1996, 271:3255-3264.
39. Mukasa R., et al. Core 2-containing O-glycans on CD43 are preferentially expressed in the memory subset of human CD4 T cells. Int. Immunol. 1999, 11:259-268.
40. Nguyen J.T., et al. CD45 modulates galectin-1-induced T cell death: regulation by expression of core 2 O-glycans. J. Immunol. 2001, 167:5697-5707.
41. Kikuchi J., et al. Not core 2 beta 1,6-N-acetylglucosaminyltransferase-2 or -3 but -1 regulates sialyl-Lewis x expression in human precursor B cells. Glycobiology 2005, 15:271-280.
42. Lanteri M., et al. Altered T cell surface glycosylation in HIV-1 infection results in increased susceptibility to galectin-1-induced cell death. Glycobiology 2003, 13:909-918.
43. Huang M.C., et al. C2GnT-M is downregulated in colorectal cancer and its re-expression causes growth inhibition of colon cancer cells. Oncogene 2006, 25:3267-3276.
44. McBride D.S., et al. Detection of glycosyltransferases in the golden hamster (Mesocricetus auratus) oviduct and evidence for the regulation of O-glycan biosynthesis during the estrous cycle. Biochim. Biophys. Acta 2005, 1721:107-115.
45. Schwientek T., et al. Functional conservation of subfamilies of putative UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferases in Drosophila, Caenorhabditis elegans, and mammals. One subfamily composed of l(2)35Aa is essential in Drosophila. J. Biol. Chem. 2002, 277:22623-22638.
46. Ten Hagen K.G., et al. Functional characterization and expression analysis of members of the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase family from Drosophila melanogaster. J. Biol. Chem. 2003, 278:35039-35048.
47. ten Hagen K.G., et al. Glycobiology on the fly: developmental and mechanistic insights from Drosophila. Glycobiology 2009, 19:102-111.
48. Topaz O., et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat. Genet. 2004, 36:579-581.
49. Kato K., et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J. Biol. Chem. 2006, 281:18370-18377.
50. Kathiresan S., et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 2008, 40:189-197.
51. Willer C.J., et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 2008, 40:161-169.
52. Teslovich T.M., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
53. Gram Schjoldager K.T., et al. O-glycosylation modulates proprotein convertase activation of angiopoietin-like protein 3 - possible role of polypeptide GalNAc-transferase-2 in regulation of concentrations of plasma lipids. J. Biol. Chem. 2010, 285:36293-36303.
54. Miwa H.E., et al. Isoform-specific O-glycosylation of osteopontin and bone sialoprotein by polypeptide N-acetylgalactosaminyltransferase-1. J. Biol. Chem. 2010, 285:1208-1219.
55. Zhang L., et al. An O-glycosyltransferase promotes cell adhesion during development by influencing secretion of an extracellular matrix integrin ligand. J. Biol. Chem. 2010, 285:19491-19501.
56. Bennett E.P., et al. Cloning and characterization of a close homologue of human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6. Evidence for genetic but not functional redundancy. J. Biol. Chem. 1999, 274:25362-25370.
57. Fritz T.A., et al. The beginnings of mucin biosynthesis: the crystal structure of UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferase-T1. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15307-15312.
58. Fritz T.A., et al. Dynamic association between the catalytic and lectin domains of human UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferase-2. J. Biol. Chem. 2006, 281:8613-8619.
59. Kubota T., et al. Structural basis of carbohydrate transfer activity by human UDP-GalNAc: polypeptide alpha-N-acetylgalactosaminyltransferase (pp-GalNAc-T10). J. Mol. Biol. 2006, 359:708-727.
60. Gerken T.A., et al. Conservation of peptide acceptor preferences between Drosophila and mammalian polypeptide-GalNAc transferase ortholog pairs. Glycobiology 2008, 18:861-870.
61. Bennett E.P., et al. Rescue of Drosophila melanogaster l(2)35Aa lethality is only mediated by polypeptide GalNAc-transferase pgant35A, but not by the evolutionary conserved human ortholog GalNAc-transferase-T11. Glycoconj. J. 2010, 27:435-444.
62. Bennett E.P., et al. A novel human UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase, GalNAc-T7, with specificity for partial GalNAc-glycosylated acceptor substrates. FEBS Lett. 1999, 460:226-230.
63. Ten Hagen K.G., et al. Characterization of a UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase that displays glycopeptide N-acetylgalactosaminyltransferase activity. J. Biol. Chem. 1999, 274:27867-27874.
64. Hanisch F.G., et al. Evidence for glycosylation-dependent activities of polypeptide N-acetylgalactosaminyltransferases rGalNAc-T2 and -T4 on mucin glycopeptides. Glycobiology 2001, 11:731-740.
65. Gerken T.A., et al. Identification of common and unique peptide substrate preferences for the UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferases T1 and T2 derived from oriented random peptide substrates. J. Biol. Chem. 2006, 281:32403-32416.
66. Pratt M.R., et al. Deconvoluting the functions of polypeptide N-alpha-acetylgalactosaminyltransferase family members by glycopeptide substrate profiling. Chem. Biol. 2004, 11:1009-1016.
67. Perrine C.L., et al. Glycopeptide-preferring polypeptide GalNAc transferase 10 (ppGalNAc T10), involved in mucin-type O-glycosylation, has a unique GalNAc-O-Ser/Thr-binding site in its catalytic domain not found in ppGalNAc T1 or T2. J. Biol. Chem. 2009, 284:20387-20397.
68. Kato K., et al. N-acetylgalactosamine incorporation into a peptide containing consecutive threonine residues by UDP-N-acetyl-D-galactosaminide:polypeptide N-acetylgalactosaminyltransferases. Glycobiology 2001, 11:821-829.
69. Hassan H., et al. The lectin domain of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-T4 directs its glycopeptide specificities. J. Biol. Chem. 2000, 275:38197-38205.
70. Raman J., et al. The catalytic and lectin domains of UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferase function in concert to direct glycosylation site selection. J. Biol. Chem. 2008, 283:22942-22951.
71. Kinarsky L., et al. Conformational studies on the MUC1 tandem repeat glycopeptides: implication for the enzymatic O-glycosylation of the mucin protein core. Glycobiology 2003, 13:929-939.
72. Tenno M., et al. Function of the lectin domain of polypeptide N-acetylgalactosaminyltransferase 1. Biochem. Biophys. Res. Commun. 2002, 298:755-759.
73. Wandall H.H., et al. The lectin domains of polypeptide GalNAc-transferases exhibit carbohydrate-binding specificity for GalNAc: lectin binding to GalNAc-glycopeptide substrates is required for high density GalNAc-O-glycosylation. Glycobiology 2007, 17:374-387.
74. Ten Hagen K.G., et al. Cloning and characterization of a ninth member of the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase family, ppGaNTase-T9. J. Biol. Chem. 2001, 276:17395-17404.
75. Roth J., et al. Demonstration of an extensive trans-tubular network continuous with the Golgi apparatus stack that may function in glycosylation. Cell 1985, 43:287-295.
76. Roth J., et al. Subcellular localization of the UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-mediated O-glycosylation reaction in the submaxillary gland. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:8935-8939.
77. Skrincosky D., et al. Altered Golgi localization of core 2 beta-1,6-N-acetylglucosaminyltransferase leads to decreased synthesis of branched O-glycans. J. Biol. Chem. 1997, 272:22695-22702.
78. Rottger S., et al. Localization of three human polypeptide GalNAc-transferases in HeLa cells suggests initiation of O-linked glycosylation throughout the Golgi apparatus. J. Cell Sci. 1998, 111(Pt 1):45-60.
79. Whitehouse C., et al. A transfected sialyltransferase that is elevated in breast cancer and localizes to the medial/trans-Golgi apparatus inhibits the development of core-2-based O-glycans. J. Cell Biol. 1997, 137:1229-1241.
80. Hayes B.K., Varki A. The biosynthesis of oligosaccharides in intact Golgi preparations from rat liver. Analysis of N-linked and O-linked glycans labeled by UDP-[6-3H]N-acetylgalactosamine. J. Biol. Chem. 1993, 268:16170-16178.
81. Ikehara Y., et al. Cloning and expression of a human gene encoding an N-acetylgalactosamine-alpha2,6-sialyltransferase (ST6GalNAc I): a candidate for synthesis of cancer-associated sialyl-Tn antigens. Glycobiology 1999, 9:1213-1224.
82. Marcos N.T., et al. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res. 2004, 64:7050-7057.
83. Sewell R., et al. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J. Biol. Chem. 2006, 281:3586-3594.
84. Julien S., et al. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology 2006, 16:54-64.
85. Bard F., et al. Src regulates Golgi structure and KDEL receptor-dependent retrograde transport to the endoplasmic reticulum. J. Biol. Chem. 2003, 278:46601-46606.
86. Gill D.J., et al. Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes. J. Cell Biol. 2010, 189:843-858.
87. Perez-Vilar J., et al. Presence of terminal N-acetylgalactosamine residues in subregions of the endoplasmic reticulum is influenced by cell differentiation in culture. J. Biol. Chem. 1991, 266:23967-23976.
88. Mandel U., et al. Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family. Glycobiology 1999, 9:43-52.
89. Kim J.H., et al. Dynamic measurement of the pH of the Golgi complex in living cells using retrograde transport of the verotoxin receptor. J. Cell Biol. 1996, 134:1387-1399.
90. Demaurex N., et al. Mechanism of acidification of the trans-Golgi network (TGN). In situ measurements of pH using retrieval of TGN38 and furin from the cell surface. J. Biol. Chem. 1998, 273:2044-2051.
91. Guarino M. Src signaling in cancer invasion. J. Cell Physiol. 2010, 223:14-26.
92. Yeatman T.J. A renaissance for SRC. Nat. Rev. Cancer 2004, 4:470-480.
93. Frame M.C. Newest findings on the oldest oncogene; how activated src does it. J. Cell Sci. 2004, 117:989-998.
94. Gerken T.A., et al. Site-specific core 1 O-glycosylation pattern of the porcine submaxillary gland mucin tandem repeat. Evidence for the modulation of glycan length by peptide sequence. J. Biol. Chem. 1998, 273:26580-26588.
95. Brockhausen I., et al. Site directed processing: Role of amino acid sequences and glycosylation of acceptor glycopeptides in the assembly of extended mucin type O-glycan core 2. Biochim. Biophys. Acta 2009, 1790:1244-1257.
96. Dalziel M., et al. The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1. J. Biol. Chem. 2001, 276:11007-11015.
97. Yu L.G., et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J. Biol. Chem. 2007, 282:773-781.
98. Ju T., Cummings R.D. Protein glycosylation: chaperone mutation in Tn syndrome. Nature 2005, 437:1252.
99. Pinho S., et al. Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett. 2007, 249:157-170.
100. Kim L.C., et al. Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 2009, 6:587-595.
101. Ashkenazy H., et al. ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic Acids Res. 2010, 38(Suppl.):W529-W533.
102. Landau M., et al. ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures. Nucleic Acids Res. 2005, 33:W299-W302.